![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Biocomposites adds Mexico to its list of countries where STIMULAN is approved as an antibiotic carrier for use in bone and soft tissue
STIMULAN® gives surgeons the freedom to choose and combine the…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Panel Summaries from Optimum’s 14th Annual Healthcare Investor Conference 2022
For those that were unable to attend on Optimum’s 14th Annual…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
STORM Therapeutics doses first patient with oral METTL3 targeting drug candidate in a solid tumor Phase 1 study
23 November 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM),…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
ImaginAb Executes New License and Supply Agreement for CD8 ImmunoPET Technology with TriSalus Life Sciences
Los Angeles, California, USA, November 22nd, 2022 – ImaginAb…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Dan Mahony & Gareth Powell – Global healthcare investing: Can hindsight hone the crystal ball for the future? A fireside chat moderated by Amy Brown, Evaluate Vantage
Dan Mahony and Gareth Powell are long time, successful life sciences…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Synaffix Named ‘Biotech Company of the Year’ at the LSX European Lifestars Awards
AMSTERDAM, THE NETHERLANDS, November 16, 2022 – Synaffix B.V.…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
ImaginAb Executes License and Supply Agreement for CD8 ImmunoPET Technology with DynamiCure Biotechnology
Los Angeles, California, USA, November 15, 2022 – ImaginAb…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Destiny Pharma plc – XF-73 Dermal infection project advances into clinically enabling safety study as part of ongoing agreement with US Government’s NIAID
Brighton, United Kingdom, 15th November 2022 - Destiny Pharma…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first patient dosed successfully with DSR 2.0 in YUKON
PRESS RELEASE
REGULATED INFORMATION – INSIDE INFORMATION
15…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Leading Pharma & Biotech Journalist Richard Staines Joins Optimum
14 November 2022 - Optimum Strategic Communications ("Optimum"),…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Financing growth: Walking the tightrope – Annual Healthcare Investor Conference Insight
Financing growth: Walking the tightrope
InsightIn the context…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Parthenon Therapeutics and ImaginAb Announce License and Supply Agreement to Advance New Class of Anti-Cancer Therapies’ Clinical Development Program
Agreement enables use of CD8 ImmunoPETTM Imaging Technology…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Novo Holdings and Sound Bioventures launch Breye Therapeutics to develop novel oral therapies for ophthalmologic diseases
Industry expert Ulrik Mouritzen M.D. appointed Chief Executive…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Minoryx and Neuraxpharm announce a strategic alliance to provide a new therapy for rare CNS disease patients in Europe
The companies enter into a license agreement for the European…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Access to up to $400 million expected to provide cash runway…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Sequana Medical to present at Jefferies London Healthcare Conference
Ghent, Belgium – 8 November 2022 – Sequana Medical NV (Euronext…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
First-in-Human Study: Amplivant® Adjuvant Boosts Immune Response of Synthetic Long Peptide Immunotherapy
First-in-human study investigating the safety and immunogenicity…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
Can private markets continue to drive development in Life Sciences? – Insights from Optimum’s Healthcare Conference
We were proud to host a fantastic panel chaired by BioCentury’s…
![](https://www.optimumcomms.com/wp-content/uploads/2023/05/OPT_Logo_300x180px-80x80Web_Logos-260x180.png)
CellCentric to present inobrodib Phase I multiple myeloma efficacy and safety data at the American Society of Haematology
Inobrodib is a pioneering drug targeting twin tumour drivers…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York